Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Jul 21;8:27.
doi: 10.1186/1471-2377-8-27.

Rapid Improvement in Verbal Fluency and Aphasia Following Perispinal Etanercept in Alzheimer's Disease

Affiliations
Free PMC article
Clinical Trial

Rapid Improvement in Verbal Fluency and Aphasia Following Perispinal Etanercept in Alzheimer's Disease

Edward L Tobinick et al. BMC Neurol. .
Free PMC article

Abstract

Background: Recent clinical studies point to rapid and sustained clinical, cognitive, and behavioral improvement in both Alzheimer's disease and primary progressive aphasia following weekly perispinal administration of etanercept, a TNF-alpha inhibitor that acts by blocking the binding of this cytokine to its receptors. This outcome is concordant with recent basic science studies suggesting that TNF-alpha functions in vivo as a gliotransmitter that regulates synaptic function in the brain. We hypothesized that perispinal etanercept had the potential to improve verbal function in Alzheimer's disease, so we included several standarized measures of verbal ability to evaluate language skills in a clinical trial of perispinal etanercept for Alzheimer's disease.

Methods: This was a prospective, single-center, open-label, pilot study, in which 12 patients with mild-to-severe Alzheimer's disease were administered etanercept, 25-50 mg, weekly by perispinal administration for six months. Two additional case studies are presented.

Results: Two-tailed, paired t-tests were conducted comparing baseline performance to 6-month performance on all neuropsychological measures. Test batteries included the California Verbal Learning Test-Second Edition, Adult Version; Logical Memory I and II(WMS-LM-II) from the Wechsler Memory Scale-Abbreviated; the Comprehensive Trail Making Test (TMT); Boston Naming Test; and letter(FAS) and category verbal fluency. All measures revealed a significant effect except for the Boston Naming Test and the TMT-4, with WMS-LM-II being marginally significant at p = .05. The FAS test for letter fluency was most highly significant with a p < 0.0007. In addition, rapid improvement in verbal fluency and aphasia in two patients with dementia, beginning minutes after perispinal etanercept administration, is documented.

Conclusion: In combination with the previously reported results of perispinal etanercept in Alzheimer's disease and primary progressive aphasia, these results further argue that larger scale studies of this therapeutic intervention, including Phase 3 trials, are warranted in dementias. In addition, these results may provide insight into the basic pathophysiologic mechanisms underlying Alzheimer's disease and related forms of dementia, and suggest the existence of novel, rapidly reversible, TNF-mediated pathophysiologic mechanisms in Alzheimer's disease which are worthy of further investigation.

Figures

Figure 1
Figure 1
Changes in verbal fluency, learning, and memory over 6 months during maintenance treatment with perispinal etanercept in a 12 subject pilot study, as reflected by T-score change from baseline to 6 months. Two-tailed, paired t-tests were conducted comparing baseline performance to 6-month performance on all neuropsychological measures. Abbreviations: California Verbal Learning Test-Second Edition, Adult Version (CVLT-II), including tests 1–5 and slope of change; Logical Memory I (LMI), and II (LMII) from the Wechsler Memory Scale-Abbreviated (WMS-a); the Comprehensive Trail Making Test (TMT), including tests 1 (TMT-1) and 4 (more difficult) (TMT-4); Boston Naming Test; and letter(FAS) and category(animal) verbal fluency.
Figure 2
Figure 2
FDG-PET brain scan of a patient with non-fluent aphasia secondary to Alzheimer's disease (case report 2), prior to treatment, demonstrating decreased glucose metabolism in the left parietal, bilateral temporal, and left frontal lobe.

Similar articles

See all similar articles

Cited by 35 articles

See all "Cited by" articles

References

    1. Tobinick E. Perispinal etanercept for treatment of Alzheimer's Disease. Curr Alzheimer Res. 2007;4:550–552. doi: 10.2174/156720507783018217. - DOI - PubMed
    1. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Medscape General Medicine. 2006;8:25. - PMC - PubMed
    1. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation. 2008;5:2. doi: 10.1186/1742-2094-5-2. - DOI - PMC - PubMed
    1. Griffin WS. Perispinal etanercept: Potential as an Alzheimer therapeutic. J Neuroinflammation. 2008;5:3. doi: 10.1186/1742-2094-5-3. - DOI - PMC - PubMed
    1. Ramos EM, Lin MT, Larson EB, Maezawa I, Tseng LH, Edwards KL, Schellenberg GD, Hansen JA, Kukull WA, Jin LW. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol. 2006;63:1165–9. doi: 10.1001/archneur.63.8.1165. - DOI - PubMed

MeSH terms

Feedback